ATE413883T1 - Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose - Google Patents

Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose

Info

Publication number
ATE413883T1
ATE413883T1 AT02747932T AT02747932T ATE413883T1 AT E413883 T1 ATE413883 T1 AT E413883T1 AT 02747932 T AT02747932 T AT 02747932T AT 02747932 T AT02747932 T AT 02747932T AT E413883 T1 ATE413883 T1 AT E413883T1
Authority
AT
Austria
Prior art keywords
carbon monoxide
tissue
suppresses apoptosis
organ transplantations
improves results
Prior art date
Application number
AT02747932T
Other languages
English (en)
Inventor
Fritz Bach
Edda Tobiasch
Miguel Soares
Leo OTTERBEIN
Jeanne GOSE
Original Assignee
Beth Israel Hospital
Univ Yale
Jeanne GOSE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404726&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE413883(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beth Israel Hospital, Univ Yale, Jeanne GOSE filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE413883T1 publication Critical patent/ATE413883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02747932T 2001-06-21 2002-06-21 Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose ATE413883T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30028901P 2001-06-21 2001-06-21
US33434001P 2001-11-29 2001-11-29
US33797401P 2001-12-07 2001-12-07

Publications (1)

Publication Number Publication Date
ATE413883T1 true ATE413883T1 (de) 2008-11-15

Family

ID=27404726

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02747932T ATE413883T1 (de) 2001-06-21 2002-06-21 Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose

Country Status (26)

Country Link
US (2) US7238469B2 (de)
EP (2) EP1404811B1 (de)
JP (1) JP4521183B2 (de)
KR (1) KR20040032115A (de)
CN (1) CN100502650C (de)
AT (1) ATE413883T1 (de)
AU (2) AU2002318377B2 (de)
BG (1) BG108492A (de)
BR (1) BR0210599A (de)
CA (1) CA2451266A1 (de)
CY (1) CY1108798T1 (de)
CZ (1) CZ20033448A3 (de)
DE (1) DE60229848D1 (de)
DK (1) DK1404811T3 (de)
ES (1) ES2316583T3 (de)
HK (1) HK1067380A1 (de)
HU (1) HUP0400371A3 (de)
MX (1) MXPA03012031A (de)
NO (1) NO20035637L (de)
NZ (1) NZ562962A (de)
PL (1) PL367544A1 (de)
PT (1) PT1404811E (de)
SG (1) SG147305A1 (de)
SI (1) SI1404811T1 (de)
SK (1) SK15942003A3 (de)
WO (1) WO2003000114A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
AU2002318377B2 (en) * 2001-06-21 2008-06-19 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
EP1476168A2 (de) 2002-02-04 2004-11-17 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Verwendung von co-freisetzenden molekülen zur behandlung von entzündlichen krankheiten
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
CN100393323C (zh) 2002-02-13 2008-06-11 贝思·伊斯雷尔·迪科尼斯医药中心 治疗血管疾病的方法
ES2554108T3 (es) 2002-04-15 2015-12-16 University Of Pittburgh Of The Commonwealth System Of Higher Education Métodos de tratamiento de la enterocolitis necrosante
CN100496509C (zh) 2002-04-15 2009-06-10 联邦高等教育***匹兹堡大学 一氧化碳产品及其对于肠梗阻的用途
US8097585B2 (en) * 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
UA83465C2 (uk) 2002-05-17 2008-07-25 Йельский Университет Спосіб лікування гепатитів монооксидом вуглецю
EP1509237A4 (de) * 2002-06-05 2006-07-12 Univ Yale Verfahren zur behandlung von angiogenese, tumorwachstum und metastasen
CA2490392A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
CA2504604A1 (en) * 2002-11-07 2004-05-27 Timothy R. Billiar Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
WO2005041655A1 (en) * 2003-10-22 2005-05-12 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
EP1552840A1 (de) * 2004-01-07 2005-07-13 Aga Ab Mischung aus Xenon und Kohlenmonoxyd zum Schutz von Zellen
EP1863503B1 (de) * 2005-03-07 2019-05-22 Sangart, Inc. Zusammensetzung zur abgabe von kohlenmonoxid (co) und stickoxid (no) an gewebe unter verwendung von heme-proteinen als träger
WO2007014380A2 (en) 2005-07-27 2007-02-01 University Of North Carolina At Charlotte Composition and method for the restoration and preservation of transplant organs procured from dcd donors
US20070207993A1 (en) * 2005-12-20 2007-09-06 Alfama - Investigacao E Desenvolvimetno De Productos Farmaceuticos Lda Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
EP2099463B1 (de) 2006-11-07 2014-07-16 The General Hospital Corporation Minderung von vasoaktiver sauerstoffträger-induzierter gefässverengung
WO2010138114A1 (en) 2009-05-27 2010-12-02 Ikaria Holdings, Inc. Devices and methods for engaging indexed valve and pressurized canister assembly with collar and for linear actuation by plunger assembly into fluid communication with device for regulating drug delivery
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
CN109925318A (zh) 2011-01-14 2019-06-25 洛杉矶儿童医院 用于治疗包括镰状细胞疾病的疾病的一氧化碳溶液
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
WO2012125955A2 (en) 2011-03-16 2012-09-20 Mayo Foundation For Medical Education And Research Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
WO2012145520A2 (en) 2011-04-19 2012-10-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
CA2838829A1 (en) * 2011-06-10 2012-12-13 Geno Llc Pressurized vessel of nitric oxide (no)
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
EP2741821A4 (de) 2011-08-09 2015-10-07 Beth Israel Hospital Verfahren zur behandlung von dna-schäden
US9629358B2 (en) 2013-03-15 2017-04-25 Mallinckrodt Hospital Products IP Limited Administration and monitoring of nitric oxide in ex vivo fluids
US10667510B2 (en) 2013-03-15 2020-06-02 Mallinckrodt Hospital Products IP Limited Administration and monitoring of nitric oxide in ex vivo fluids
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
CN105288599A (zh) * 2015-10-22 2016-02-03 徐州医学院 血红素氧化酶-2在制备抑制器官移植免疫排斥制剂中的应用
EP3672403A4 (de) 2017-08-25 2021-05-19 Mallinckrodt Hospital Products IP Limited Verfahren zur verbesserung der organlebensfähigkeit
EP3524290A1 (de) 2018-02-09 2019-08-14 Julius-Maximilians-Universitaet Wuerzburg Verfahren und system zur überwachung der kohlenmonoxid(co)-verabreichung an ex-vivo-flüssigkeiten
CN116076484A (zh) * 2022-11-30 2023-05-09 武汉大学 一种修复肾脏损伤的低温携氧机械灌注液及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5293875A (en) 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
AU6523194A (en) * 1993-03-26 1994-10-24 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5763431A (en) 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US6063407A (en) 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5712293A (en) 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) * 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
DK0835115T3 (da) 1995-06-30 2004-08-02 Zymogenetics Inc 4-(2-(N-2-carboxamidoindo)aminoethyl)-benzensulfonamider eller -sulfonylurinstoffer som PDGF-antagonister
PT914103E (pt) 1996-04-05 2006-09-29 Gen Hospital Corp Tratamento de uma hemoglobinopatia
US6069132A (en) 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
JP2000517311A (ja) 1996-08-27 2000-12-26 メッサー グリースハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング 水素含有薬剤
ATE358492T1 (de) * 1996-09-27 2007-04-15 Univ Columbia Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6316403B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US5869538A (en) * 1996-11-26 1999-02-09 Research Foundation Of State University Of New York Method for enhancing transport of gases to tissues
FR2757259B1 (fr) * 1996-12-18 1999-03-05 Valeo Thermique Moteur Sa Ailette metallique perfectionnee pour echangeur de chaleur, notamment pour vehicule automobile
US5912019A (en) * 1997-02-07 1999-06-15 Musc Foundation For Research Development Compounds for reducing ischemia/reperfusion injury
CA2321920C (en) 1998-03-16 2010-05-25 Hon-Wah Man 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US6203991B1 (en) 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6558825B1 (en) * 2000-05-12 2003-05-06 Reveo, Inc. Fuel containment and recycling system
FR2812197B1 (fr) 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
BR0208012A (pt) 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
MXPA03008820A (es) * 2001-03-30 2004-07-30 Sangstat Medical Corp Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos.
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
DE60202677T2 (de) 2001-05-25 2005-12-29 Medtronic, Inc., Minneapolis Implantierbare medizinische vorrichtung mit kontrollierter freigabe von gasförmigen mitteln
AU2002318377B2 (en) 2001-06-21 2008-06-19 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
EP1476168A2 (de) 2002-02-04 2004-11-17 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Verwendung von co-freisetzenden molekülen zur behandlung von entzündlichen krankheiten
CN100393323C (zh) * 2002-02-13 2008-06-11 贝思·伊斯雷尔·迪科尼斯医药中心 治疗血管疾病的方法
ES2554108T3 (es) * 2002-04-15 2015-12-16 University Of Pittburgh Of The Commonwealth System Of Higher Education Métodos de tratamiento de la enterocolitis necrosante
US8097585B2 (en) * 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
CN100496509C (zh) * 2002-04-15 2009-06-10 联邦高等教育***匹兹堡大学 一氧化碳产品及其对于肠梗阻的用途
UA83465C2 (uk) * 2002-05-17 2008-07-25 Йельский Университет Спосіб лікування гепатитів монооксидом вуглецю
EP1509237A4 (de) * 2002-06-05 2006-07-12 Univ Yale Verfahren zur behandlung von angiogenese, tumorwachstum und metastasen
CA2490392A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
CA2504604A1 (en) * 2002-11-07 2004-05-27 Timothy R. Billiar Treatment for hemorrhagic shock
WO2005077005A2 (en) * 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas

Also Published As

Publication number Publication date
DK1404811T3 (da) 2009-03-02
EP1404811A2 (de) 2004-04-07
EP2033514A2 (de) 2009-03-11
CY1108798T1 (el) 2014-04-09
NZ562962A (en) 2009-08-28
AU2002318377B2 (en) 2008-06-19
AU2008221551A1 (en) 2008-10-09
EP1404811A4 (de) 2006-08-09
PL367544A1 (en) 2005-02-21
HUP0400371A2 (hu) 2004-08-30
SG147305A1 (en) 2008-11-28
SI1404811T1 (sl) 2009-04-30
CN1545548A (zh) 2004-11-10
CN100502650C (zh) 2009-06-24
BG108492A (en) 2005-02-28
EP1404811B1 (de) 2008-11-12
BR0210599A (pt) 2004-07-20
CA2451266A1 (en) 2003-01-03
US20030039638A1 (en) 2003-02-27
US7238469B2 (en) 2007-07-03
MXPA03012031A (es) 2005-07-01
PT1404811E (pt) 2009-01-22
WO2003000114A3 (en) 2003-04-10
KR20040032115A (ko) 2004-04-14
WO2003000114A2 (en) 2003-01-03
NO20035637L (no) 2004-02-17
NO20035637D0 (no) 2003-12-17
US20070202083A1 (en) 2007-08-30
HK1067380A1 (en) 2005-04-08
ES2316583T3 (es) 2009-04-16
JP2005500875A (ja) 2005-01-13
SK15942003A3 (sk) 2004-08-03
HUP0400371A3 (en) 2010-06-28
WO2003000114A9 (en) 2004-05-21
JP4521183B2 (ja) 2010-08-11
CZ20033448A3 (cs) 2004-05-12
EP2033514A3 (de) 2009-04-29
DE60229848D1 (de) 2008-12-24

Similar Documents

Publication Publication Date Title
ATE413883T1 (de) Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
WO2004009767A3 (en) Cell therapy for regeneration
WO2004047747A3 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
WO2003040346A3 (en) Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
DE69941903D1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
EP1406643A4 (de) Physiologische gewebereparatur und funktionale organregeneration durch kultivierung von regenerativen stammzellen in vivo und in situ
ECSP066422A (es) Método para obtener factores citotóxicos provenientes de microorganismos, factores citotóxicos obtenidos y composición farmacéutica y conjunto que los contienen.
WO2004101758A3 (en) Composition for maintaining organ and cell viability
HK1065074A1 (en) Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
WO2003012060A3 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
DK1274464T3 (da) Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
EP2216033A3 (de) Behandlungsmethode einer Erkrankung durch Transplantation eines allogenen oder xenogenen Organs oder Gewebe
EP2527427A3 (de) Multipotente Postnatale Stammzellen aus dem humanen periodontalen Ligament und deren Verwendung
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
IL190289A0 (en) Method for obtaining human smooth muscular cells and uses thereof
WO2003078607A3 (en) Tissue specific signal-plexes to dedifferentiate and redifferentiate cells
DK1185621T3 (da) Overflade til cellekultur
WO2003029432A3 (en) Human mesenchymal progenitor cell
HUP0103107A2 (hu) Allogénikus és xenogénikus T-sejtek ex vivo kezelése gp39 antagonistákkal
WO2004000213A3 (en) Method for growing human organs, treating diseases, and increasing longevity
Court Spanish Constitutional Court. Ruling of 19 of December of 1996. the challenge on the grounds of inconstitutionality against law 42/1988, of 28 December, regulating the donation and use of human embryos and foetuses or the cells, tissues or organs therefrom
RU2005132000A (ru) Способ омоложения и лечения кожи, печени, почек и других органов человека и животных

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1404811

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked